Rheumatoid Arthritis Treatment Guidelines

Initial Treatment Approach

The American College of Rheumatology recommends methotrexate monotherapy as the first-line treatment for DMARD-naive patients with rheumatoid arthritis and moderate-to-high disease activity, initiated at 7.5-10 mg weekly and rapidly escalated to at least 15 mg within 4-6 weeks 1, 2
Methotrexate is strongly recommended over all other options, including hydroxychloroquine, sulfasalazine, leflunomide, biologic DMARDs, and targeted synthetic DMARDs, due to its established efficacy, safety profile, and lower cost 1, 3

The American College of Rheumatology recommends starting oral methotrexate at 7.5-10 mg weekly and rapidly escalating to at least 15 mg within 4-6 weeks, with a target dose of 20-25 mg weekly for optimal disease control 2, 4
Folic acid supplementation is strongly recommended to reduce side effects 4

The American College of Rheumatology recommends against the use of long-term glucocorticoids (≥3 months) and conditionally recommends short-term glucocorticoids (<3 months) as bridging therapy while awaiting DMARD effect 1, 4

The American College of Rheumatology recommends a treat-to-target approach, with a target goal of low disease activity, defined as SDAI ≤11 or CDAI ≤10, and remission defined as SDAI ≤3.3 or CDAI ≤2.8 5, 6, 7
Disease activity should be monitored every 1-3 months, with treatment adjustments made as needed to achieve target 4

For patients on maximally tolerated methotrexate monotherapy who do not achieve target, the American College of Rheumatology conditionally recommends adding conventional synthetic DMARDs (triple therapy) or biologic/targeted synthetic DMARDs 5, 7, 4

The American College of Rheumatology recommends prophylactic antiviral therapy for hepatitis B core antibody positive patients initiating rituximab or any biologic/targeted synthetic DMARD if surface antigen positive 8
Non-TNF inhibitor biologics or targeted synthetic DMARDs are conditionally recommended over TNF inhibitors for patients with heart failure (NYHA class III or IV) 8